ES2829614T3 - Composición farmacéutica que comprende una neurotoxina botulínica y usos de la misma - Google Patents
Composición farmacéutica que comprende una neurotoxina botulínica y usos de la misma Download PDFInfo
- Publication number
- ES2829614T3 ES2829614T3 ES14727073T ES14727073T ES2829614T3 ES 2829614 T3 ES2829614 T3 ES 2829614T3 ES 14727073 T ES14727073 T ES 14727073T ES 14727073 T ES14727073 T ES 14727073T ES 2829614 T3 ES2829614 T3 ES 2829614T3
- Authority
- ES
- Spain
- Prior art keywords
- botulinum toxin
- chitosan
- composition
- composition according
- botulinum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 100
- 231100001103 botulinum neurotoxin Toxicity 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 54
- 229920001661 Chitosan Polymers 0.000 claims abstract description 70
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 18
- 238000003381 deacetylation reaction Methods 0.000 claims abstract description 7
- 230000006196 deacetylation Effects 0.000 claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 239000007972 injectable composition Substances 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 141
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 78
- 229940053031 botulinum toxin Drugs 0.000 claims description 77
- 229940094657 botulinum toxin type a Drugs 0.000 claims description 70
- 238000009472 formulation Methods 0.000 claims description 54
- 238000002347 injection Methods 0.000 claims description 40
- 239000007924 injection Substances 0.000 claims description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 39
- 239000000243 solution Substances 0.000 claims description 37
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 23
- 206010003119 arrhythmia Diseases 0.000 claims description 20
- 239000011780 sodium chloride Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 208000037849 arterial hypertension Diseases 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 31
- 229920000669 heparin Polymers 0.000 description 29
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 27
- 238000000034 method Methods 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 16
- 229960002897 heparin Drugs 0.000 description 16
- 241000700159 Rattus Species 0.000 description 13
- 108010024001 incobotulinumtoxinA Proteins 0.000 description 13
- 229960000899 nadroparin Drugs 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 229940018272 xeomin Drugs 0.000 description 13
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 10
- 239000003053 toxin Substances 0.000 description 10
- 231100000765 toxin Toxicity 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- 238000007918 intramuscular administration Methods 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 108090000783 Renin Proteins 0.000 description 7
- 102100028255 Renin Human genes 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 230000001515 vagal effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000002016 disaccharides Chemical class 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000005246 left atrium Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000002254 renal artery Anatomy 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229920002101 Chitin Polymers 0.000 description 3
- 241000193155 Clostridium botulinum Species 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940089093 botox Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940098753 dysport Drugs 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- 210000001186 vagus nerve Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 206010044074 Torticollis Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- -1 carrier Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000000574 ganglionic effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 2
- 229960004359 iodixanol Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000005248 left atrial appendage Anatomy 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 230000007383 nerve stimulation Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 210000000063 presynaptic terminal Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000003492 pulmonary vein Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 208000033988 Device pacing issue Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100027612 Kallikrein-11 Human genes 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 241000238070 Pandalus borealis Species 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 206010034476 Pericardial haemorrhage Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010067672 Spasmodic dysphonia Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 101710152431 Trypsin-like protease Proteins 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001158 adipocyte of epicardial fat Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003126 arrythmogenic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003192 autonomic ganglia Anatomy 0.000 description 1
- 230000036617 axillary hyperhidrosis Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 201000002303 hemopericardium Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 210000003105 phrenic nerve Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000023027 regulation of systemic arterial blood pressure by carotid body chemoreceptor signaling Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940016052 sodium hyaluronate 10 mg/ml Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- 201000002849 spasmodic dystonia Diseases 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 206010046947 vaginismus Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2013122509/15A RU2535115C1 (ru) | 2013-05-15 | 2013-05-15 | Фармацевтический состав, содержащий нейротоксин ботулина |
| PCT/IB2014/061417 WO2014184746A1 (en) | 2013-05-15 | 2014-05-14 | Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2829614T3 true ES2829614T3 (es) | 2021-06-01 |
Family
ID=50841919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14727073T Active ES2829614T3 (es) | 2013-05-15 | 2014-05-14 | Composición farmacéutica que comprende una neurotoxina botulínica y usos de la misma |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10258673B2 (https=) |
| EP (2) | EP3750525A1 (https=) |
| JP (1) | JP6440691B2 (https=) |
| CN (1) | CN105209014B (https=) |
| CA (1) | CA2911046C (https=) |
| DK (1) | DK2996674T3 (https=) |
| ES (1) | ES2829614T3 (https=) |
| HK (1) | HK1217173A1 (https=) |
| RU (1) | RU2535115C1 (https=) |
| WO (1) | WO2014184746A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015253045B2 (en) * | 2014-04-30 | 2020-07-16 | Allergan, Inc. | Formulations of biologics for intravesical instillation |
| DK3174523T3 (da) * | 2014-07-31 | 2020-09-28 | Allergan Inc | Formuleringer af biologiske stoffer til intravesikal instillation |
| RU2577296C1 (ru) * | 2014-12-24 | 2016-03-10 | Евгения Николаевна Анисимова | Способ выбора эффективного и безопасного местного обезболивания у пациентов с артериальной гипертензией на амбулаторном стоматологическом приеме |
| RU2651044C2 (ru) * | 2016-08-22 | 2018-04-18 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. ак. Е.Н. Мешалкина" Минздрава России) | Способ лечения желудочковых нарушений ритма сердца (варианты) |
| BR112019004935A2 (pt) | 2016-09-13 | 2019-06-04 | Allergan, Inc. | composições de toxina clostridial não proteíca estabilizada |
| JP2020525416A (ja) * | 2017-06-29 | 2020-08-27 | アドヴァイテ エルエルシー． | 眼表面障害の治療及び診断 |
| WO2019241296A1 (en) * | 2018-06-13 | 2019-12-19 | Dermata Therapeutics, Llc | Compositions for the treatment of skin conditions |
| AU2019337656A1 (en) * | 2018-09-13 | 2021-05-06 | Allergan, Inc. | Methods for treatment of masseter muscle hypertrophy |
| KR102520631B1 (ko) | 2019-10-18 | 2023-04-12 | 펜랜드 파운데이션 | 치료에 사용하기 위한 보톨리늄 독소 |
| US10960061B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
| US10987411B1 (en) | 2019-10-18 | 2021-04-27 | Penland Foundation | Treatment of chronic obstructive pulmonary disease using botulinum toxin |
| WO2021231666A1 (en) | 2020-05-15 | 2021-11-18 | Penland Foundation | Treatment of asthma using botulinum toxin |
| US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
| US11241479B2 (en) | 2019-10-18 | 2022-02-08 | Penland Foundation | Treatment methods using botulinum toxins |
| US10960060B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of cardiac arrhythmia using botulinum toxin |
| US11090371B1 (en) | 2019-10-18 | 2021-08-17 | Penland Foundation | Treatment of cirrhosis using botulinum toxin |
| US11925677B2 (en) | 2021-07-12 | 2024-03-12 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
| US10973873B1 (en) | 2019-10-18 | 2021-04-13 | Penland Foundation | Treatment of asthma using botulinum toxin |
| WO2023287729A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of acute and chronic kidney disease |
| US20250295741A1 (en) * | 2022-11-07 | 2025-09-25 | Allergan, Inc. | Prevention of post-operative atrial fibrillation with a botulinum toxin |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2884358A (en) | 1957-04-22 | 1959-04-28 | Southern California Gland Co | Process for preparing crude heparin |
| JPH06192296A (ja) * | 1992-10-28 | 1994-07-12 | Chiba Pref Gov | 治療用医薬品としての結晶ａ型ボツリヌス毒素の製造法。 |
| US6967088B1 (en) | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| US20120238504A1 (en) * | 1998-09-11 | 2012-09-20 | Solstice Neurosciences, Llc | Stable Formulations of Botulinum Toxin in Hydrogels |
| US6977080B1 (en) * | 1999-08-10 | 2005-12-20 | Allergan, Inc. | Intrapericardial botulinum toxin treatment for bradycardia |
| JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| US20040058313A1 (en) * | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US7148041B2 (en) | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
| US8073538B2 (en) * | 2003-11-13 | 2011-12-06 | Cardio Polymers, Inc. | Treatment of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart |
| WO2005049111A2 (en) * | 2003-11-13 | 2005-06-02 | Symphony Medical, Inc. | Control of cardiac arrhythmias by modification of neuronal conduction within fat pads of the heart |
| US20060228404A1 (en) * | 2004-03-04 | 2006-10-12 | Anderson Daniel G | Compositions and methods for treatment of hypertrophic tissues |
| JP2005306746A (ja) * | 2004-04-19 | 2005-11-04 | Jiyugaoka Clinic | 顔面用シワ治療剤 |
| GB2416122A (en) | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| US20060073208A1 (en) | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
| GB2419817A (en) * | 2004-10-29 | 2006-05-10 | Ipsen Ltd | Treatment of cardiac fibrillation disorders |
| WO2007019554A2 (en) * | 2005-08-08 | 2007-02-15 | Momenta Pharmaceuticals, Inc. | Polysaccharides for delivery of active agents |
| AU2007249682B2 (en) * | 2006-05-15 | 2013-05-16 | Cardiopolymers, Inc. | Post-operative control of cardiac arrhythmia by modification of neuronal signaling |
| AR061669A1 (es) | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
| US8821928B2 (en) * | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| US9044477B2 (en) * | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
| JP4999008B2 (ja) | 2008-07-15 | 2012-08-15 | 楽天株式会社 | 情報送信装置、情報送信方法、情報送信処理プログラム及び情報送信システム |
| AU2009332947C1 (en) | 2008-12-31 | 2019-01-03 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations |
| AU2015253045B2 (en) * | 2014-04-30 | 2020-07-16 | Allergan, Inc. | Formulations of biologics for intravesical instillation |
-
2013
- 2013-05-15 RU RU2013122509/15A patent/RU2535115C1/ru active
-
2014
- 2014-05-14 US US14/888,511 patent/US10258673B2/en not_active Expired - Fee Related
- 2014-05-14 HK HK16105183.8A patent/HK1217173A1/zh unknown
- 2014-05-14 CN CN201480027168.XA patent/CN105209014B/zh not_active Expired - Fee Related
- 2014-05-14 DK DK14727073.0T patent/DK2996674T3/da active
- 2014-05-14 CA CA2911046A patent/CA2911046C/en not_active Expired - Fee Related
- 2014-05-14 ES ES14727073T patent/ES2829614T3/es active Active
- 2014-05-14 JP JP2016513482A patent/JP6440691B2/ja not_active Expired - Fee Related
- 2014-05-14 WO PCT/IB2014/061417 patent/WO2014184746A1/en not_active Ceased
- 2014-05-14 EP EP20190163.4A patent/EP3750525A1/en not_active Withdrawn
- 2014-05-14 EP EP14727073.0A patent/EP2996674B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6440691B2 (ja) | 2018-12-19 |
| HK1217173A1 (zh) | 2016-12-30 |
| JP2016518442A (ja) | 2016-06-23 |
| WO2014184746A1 (en) | 2014-11-20 |
| CA2911046A1 (en) | 2014-11-20 |
| RU2535115C1 (ru) | 2014-12-10 |
| US20160114013A1 (en) | 2016-04-28 |
| CN105209014B (zh) | 2018-05-25 |
| EP3750525A1 (en) | 2020-12-16 |
| US10258673B2 (en) | 2019-04-16 |
| CN105209014A (zh) | 2015-12-30 |
| CA2911046C (en) | 2021-08-31 |
| EP2996674A1 (en) | 2016-03-23 |
| DK2996674T3 (da) | 2020-10-26 |
| EP2996674B1 (en) | 2020-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2829614T3 (es) | Composición farmacéutica que comprende una neurotoxina botulínica y usos de la misma | |
| ES2479515T3 (es) | Composición terapéutica con una neurotoxina botulínica | |
| JP5558104B2 (ja) | 心組織の保護および再生のための組成物および方法 | |
| US20250221936A1 (en) | Engineered hemichannels, engineered vesicles, and uses thereof | |
| JP2021520373A (ja) | Ｃｇｒｐを阻害する際に使用するための神経毒素 | |
| CN102238953B (zh) | 用于治疗骨关节病的可注射的聚脱氧核糖核苷酸组合物 | |
| ES2893838T3 (es) | Composición que comprende toxina botulínica | |
| KR20200027493A (ko) | 펩티드의 항-염증 용도 | |
| CN108125980A (zh) | 用于稳定的多糖制剂的组合物和方法 | |
| JP2020189870A (ja) | 関節を治療するための組成物及びキット | |
| Henning et al. | Chitosan hydrogels significantly limit left ventricular infarction and remodeling and preserve myocardial contractility | |
| WO2017152039A1 (en) | Protection and delivery of multiple therapeutic proteins | |
| CN101933897B (zh) | 注射用重组人血管内皮抑制素温度敏感性凝胶组合物 | |
| Yue et al. | An injectable in situ hydrogel platform for sustained drug release against Glioblastoma | |
| CN100577177C (zh) | 一种替尼泊苷的药用组合物、制备方法及用途 | |
| TWI737972B (zh) | 心肌再灌流的方法及套组與減緩或減少心肌再灌流損傷的方法 | |
| Liu et al. | Pharmacokinetic analysis of in vivo disposition of heparin–superoxide dismutase | |
| ES2958970T3 (es) | Composiciones para uñas con propiedades antifúngicas | |
| RU2462265C1 (ru) | Способ трансдермального введения полипептидов в организм | |
| CA3178926A1 (en) | Synergistic anti-viral pharmaceutical composition containing targeting nanoparticles | |
| WO2013135928A1 (es) | Uso de la obestatina para la regeneración muscular | |
| EP3678688A1 (en) | Heparin composition for treating ischemia |